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Rectal cancer is a distinct subset of colorectal cancer where specialized disease-speciﬁc management of the primary tumor is
required. There have been signiﬁcant developments in rectal cancer surgery at all stages of disease in particular the introduction
of local excision strategies for preinvasive and early cancers, standardized total mesorectal excision for resectable cancers
incorporating preoperative short- or long-course chemoradiation to the multimodality sequencing of treatment. Laparoscopic
surgery is also increasingly being adopted as the standard rectal cancer surgery approach following expertise of colorectal surgeons
in minimally invasive surgery gained from laparoscopic colon resections. In locally advanced and metastatic disease, combining
chemoradiation with radical surgery may achieve total eradication of disease and disease control in the pelvis. Evidence for
resection of metastases to the liver and lung have been extensively reported in the literature. The role of cytoreductive surgery
and hyperthermic intraperitoneal chemotherapy for peritoneal metastases is showing promise in achieving locoregional control of
peritoneal dissemination. This paper summarizes the recent developments in approaches to rectal cancer surgery at all these time
points of the disease natural history.
1.Introduction
Rectal cancer is often camouﬂaged to be part of colorectal
cancer with Australian statistics approximating 14225 cases
of bowel cancer in 2008 with a higher predominance among
men and those above 50 years of age [1]. Meanwhile, the
American counterpart recorded rectal and colon cancer to
be the third leading malignancy plaguing both sexes in 2012
whereby9% of deaths in each gendergroup was attributed to
the disease [2]. The risk of death before age 75 has declined
overtheyearsfromahighof1in50in1987to1in91in2007
andthisisattributedtobetterearlydetectionofprecancerous
lesions and management of the disease [1, 2].
Treatment of rectal cancer is primarily surgical and is
highly dependent on the preoperative staging [3]. Early
cancers, especially T1 tumors, have been controversially
proposed for local excision either via transanal excision or
transanal endoscopic microsurgery (TEMS) [4–6]. While
some report good outcomes measurable to radical surgery,
others beg to diﬀer prompting the need for salvage therapy
[4–7]. Later stages of cancer usually follow the traditional
approach of abdominoperineal resection (APR) or ante-
rior resection and its success at reducing local recurrence
is improved by total mesorectal excision (TME) [8, 9].
However, these procedures are associated with their own
set of morbidity and mortality [10, 11]. Other thera-
peutic modalities such as chemotherapy and radiotherapy
have been included in conjunction with surgery partic-
ularly in advanced cancers. They can be used preoper-
atively or postoperatively either to increase the chances
of a sphincter-preserving procedure to allow better qual-
ity of life or with a curative intent [12–14]. An overall
cancer-speciﬁc 5-year survival of 77% has been reported
[15].
In this paper, we seek to discuss the modern approach
to rectal cancer surgery at all disease time points from
preinvasive and early rectal cancer, resectable rectal cancer,
and locally advanced and metastatic rectal cancer with an
emphasis on presenting some of the controversies and the
accepted standards of treatment.2 International Journal of Surgical Oncology
1.1.LocalExcisionofPreinvasiveandEarlyRectalCancer. The
advent of endoscopic mucosal resection (EMR) for rectal
tumours could not have been timelier as the race to provide
a treatment that is highly eﬃcacious and of low morbidity
continues. EMR has been in practice for a few decades now
andiscommonlyusedtoaddressgastrointestinalpathologies
such as a Barrett’s oesophagus, and early gastric cancers
(EGC) with a reported local recurrence rate of 2% in EGC
[16–18]. The procedure focuses on removal of diseased
mucosal tissue or at most, the superﬁcial submucosa instead
of a full-thickness excision [16, 19]. It can be done by
means of a strip biopsy, local injection of hypertonic saline-
epinephrine in the “inject, lift and cut” technique, “cup
and suction” otherwise known as the EMR-cap technique or
EMR with band ligation. If necessary, more than one of the
aforementioned methods can be applied [16, 20, 21].
EMRisanalternativetothelocally-approachedtransanal
excision (TAE) and transanal endoscopic microsurgery
(TEMS).Generally,localexcisionofrectalcancerisindicated
for early disease that encompasses its precursor (dysplasia
or adenoma), T1 tumours that display moderate-to-well
diﬀerentiation and no lymphatic or vascular invasion [6, 16,
17, 22]. At present, it is known that EMR can be performed
on ﬂat, sessile, or lateral spreading rectal tumours [22–24].
The success of EMR is reﬂected through its high overall cure
rate with some reporting 91% for treatment-na¨ ıve patients
and others at 96% [23, 25].
One of the common consequences of EMR is bleeding
w h i c ho c c u r sf r o m1 % – 4 5 %o fc a s e s[ 26]. The bleed can
be minor and is easily manageable with haemostatic clips or
severe requiring blood transfusions or even surgery [19, 24,
26]. 0.7% to 4% of cases are complicated with perforation
which can appear later as abdominal distension and pain
necessitatingfurtheroperation[25,26].Otheradverseevents
also include postprocedural abdominal pain and serositis
[25].
While EMR is an excellent therapeutic option for rectal
tumours, it is operator dependent. Identifying the lesion
especially if it is a lateral spreading tumour can be chal-
lenging to the untrained eye as it displays subtle changes
but this is improved by a dye-staining technique [22]. A
meta-analysis showed that the chances of a complete en
bloc resection is directly proportional to experiences if the
operator [27]. Removal of diseased-tissue greater than 2cm
requires a piecemeal resection. The concern is that complete
resection and a proper histological evaluation is rendered
diﬃcult with larger lesions, thus running a risk of local
recurrence [23, 25, 28]. In spite of this, some studies showed
that the success of the resection is not statistically diﬀerent
between the two techniques [26, 29].
Complicating the procedure further is the second
attempt of EMR for recurrent lesions. Failure of the mucosa
to lift during the “inject, lift and cut” technique may occur
secondary to submucosal ﬁbrosis. The success rate of a
repeated resection is reduced from 91.0% in a treatment-
na¨ ıve patient to 74.5% in a previously attempted lesion [25].
It is reported that the time for conversion of a precursor
lesion to cancer is variable, with dwelling times in the
adenoma state ranging from 4 years to as long as 48 years
[30]. In fact, ﬂat adenomas need not necessarily be treated as
it is almost always noninvasive [22]. This questions the need
for EMR in such lesions and more so, the implication on the
patient who is no doubt heading for months of unwarranted
anxiety.
Nevertheless, EMR is a safe and eﬀective treatment
modality that is minimally invasive and only requires
conscious sedation [25, 26, 28]. It is also eﬃcient with
Moss et al. reporting a mean procedural duration of 25
minutes while another study accounted a range of 25–137
minutes [25, 29]. When possible, patients can be treated as
anoutpatientwithdischargeswithinthesameday[31,32].A
comparison between TAE and endoscopic resection showed
that the latter was associated with a signiﬁcantly shorter
hospital stay of 2.7 ± 1.1 days with a mean diﬀerence of
6.2 days [19]. Similarly, TEMS recorded a range of 0–44
days of hospitalization while EMR had a range of 0–27 days
[31]. EMR per se is not as costly as the other procedures
available, thus allowing a cheaper and less invasive option for
the patient. This translates into reduced expenditure for the
spender [20, 29, 33].
On the other hand, TEMS and TAE are not as inferior
as one might think. Lesions larger than 8cm in diameter
can be removed with good eﬀect via TEMS [34, 35]. Where
EMR may fail to completely remove the tumour, both TEMS
and TAE can compensate for it [31, 36]. First attempt of
TEMS for large rectal adenoma is reported to have a lower
early local recurrence rate at 10.2% compared to EMR at
31.0% (P<0.001) [31]. Meanwhile, low risk-T1 tumour
recurrence rate following TEMS is 0–10% while Santos et
al. reported a 12% recurrence rate following EMR [28, 37].
TAE is estimated to have a 15% local recurrence rate of
the malignancy at ﬁve years [38]. It would seem that the
recurrence rate following TAE is high compared to EMR but
contradicting this is a 32-patient study by Lee et al. which
showed no recurrences of cancer following either endoscopic
resection or TAE at a median followup of 15 months (range
6–99)[19].Studiesevaluatingthedisease-speciﬁcandoverall
survival rates (TEMS versus radical surgery and TAE versus
radical surgery) showed that the values were not statistically
signiﬁcant to one another indicating the eﬃcacy of these
procedures [5, 38].
EMR appears to be favourable as TEMS and TAE have
the added adverse eﬀects including wound breakdown,
incontinence, urgency, strictures, neuralgia, and anovaginal
ﬁstula [34, 35, 37, 39]. Barendse et al. studied both EMR
and TEMS and discovered that the former was associated
with half the percentage (12%) of postoperative complica-
tions compared to the latter (24%) [31]. However, given
the variable recurrence rates, there is some apprehension
towards EMR. In view of this, no accurate decision can really
be made. Instead, it is a judgment call by the surgeon and
more importantly the patient himself based on the local
expertise and the pros and cons of each option available. As
we push the fort of combination treatment, it is likely that
in the future, local excisional strategies will become a more
commonly adopted strategy in complete or subcomplete
responding tumors after chemoradiotherapy. However, the
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intensivefollowupisrequiredtodetectrecurrenceatthelocal
excisional site and/or mesorectal lymph nodes.
1.2. Standardized Surgery in the Era of a Multimodality
Approach for Resectable Rectal Cancer. Rectal cancer diﬀers
from colon cancer whose risk of local recurrence is low.
Its proximity to the anal sphincter also makes this a major
consideration into the surgical approach towards resection.
In the localized setting, a multimodality approach has in
recent years been developed and investigated in trials to
improve local recurrence, disease-free and overall survival
using a variety of sequences of chemotherapy and radiother-
apy. Prior to surgery, adequate local staging is paramount
in the surgical planning and accurate prediction of the
extent of bowel wall involvement may be obtained through
endorectal ultrasonography and magnetic resonance imag-
ing may serve the similar purpose but also identify the
involvement of lymph node metastases [40] .T h ea i m so f
rectal cancer surgery are to remove the tumor with an
adequate distal margin of a minimum of 2cm in the case
of a low rectal tumor with sphincter preservation or 5cm
in the case of a rectosigmoid/upper rectal tumor with
restoration of intestinal continuity through an anastomosis.
This operation is known as anterior resection. If a 2cm distal
margin cannot be secured, an abdominoperineal excision
with enbloc resection of the entire anorectum and an
end colostomy is required. Surgery should be performed
using a “no-touch” technique with high ligation of the
inferior mesenteric artery to achieve adequate lymphatic
sampling through harvesting of the sigmoid mesentery and
mesorectum.Tumorsofthemiddleandlowerrectumrequire
atotalmesorectalexcision(TME)[41].TMEreducestherisk
of local recurrence and although a prospective randomized
trialhasnotbeenconductedtoverifyitseﬃcacy,longitudinal
data derived from The Netherlands where a TME trial was
conducted following rigorous training of colorectal surgeons
demonstrated that there was an observed reduction in rate of
local recurrence from 16% to 9% with TME surgery being an
independent predictor of overall survival [42]. Further, data
from the MRC CR07 and NCIC-CTG CO16 randomized
trials demonstrated that the plane of surgery achieved in
patients undergoing rectal cancer surgery impacted on local
r e c u r r e n c e sw i t ha3 - y e a rl o c a lr e c u r r e n c er a t eo f4 %f o r
patients whose surgery was completed with achievement
of the mesorectal plane, 7% for intramesorectal plane and
13% for muscularis propria plane [43]. Pertinent also in
low rectal cancers requiring abdominoperineal excision, to
avoid a “coning eﬀect” in the deep pelvis as the tumor is
approachedfromboththeabdomenandperineum,extended
abdominoperineal excision incorporating resection of the
levator muscles to reduce inadvertent bowel perforation and
breaching of the circumferential resection margin [44].
1.2.1.LaparoscopicorOpenSurgery. Today,inthecurrentera
of laparoscopic surgery where shorter postoperative hospital
stays, reduction in pain scores, shorter time of return of
bowel function, lower treatment cost, and improved cosme-
sis may be achieved, these standardized surgical resections
have been demonstrated to be feasible in the laparoscopic
approach [45]. Initially, the laparoscopic approach was ﬁrst
examined in colon cancer with at least 4 large randomized
trials; COST Study Group trial from the USA, COLOR trial
from Europe, MRC CLASICC trial from the UK, and a trial
in rectosigmoid cancers from the Prince of Wales Hospital
in Hong Kong demonstrating equivalent oncologic eﬃcacy
with similar overall survival, disease-free survival and local
and distant recurrences [46–49]. These studies although
predominantly examined in the setting of colon cancer
were quick to translate into standard practice for rectal
cancer despite limited large scale prospective randomized
trials. However, there remain concerns over the ability to
achieve adequate mesorectal excision and clear surgical
margins in laparoscopic rectal cancer surgery. In the UK
MRC CLASICC trial, there was a 34% conversion rate from
laparoscopic to open surgery in the rectal cohort, increase
performanceofTMEsurgerytoensureadequacyofthedistal
resection margin in the laparoscopic group because of the
inability to palpate the tumor for localization. Nonetheless,
there was no diﬀerence in positive circumferential resection
margin, local recurrence, disease-free, and overall survival
in both the laparoscopic versus open anterior resection and
abdominoperineal resection groups [48].
The Prince of Wales Hospital group from Hong Kong
reportedasmallprospectiverandomizedtrialoflaparoscopic
assisted versus open abdominoperineal resection for low
rectal cancer randomizing 99 patients (51 lap-assisted and
48 open) demonstrating earlier return of bowel function,
decrease time to mobilization, lesser analgesia requirement,
longer operative time, and higher direct cost in the lap-
assisted group without diﬀerence in morbidity and mortality
[50]. In an update of this trial, after 10 years of followup,
the authors reported higher rates of bowel obstruction
requiring hospitalization and intervention in the open group
but similar oncologic outcomes were shown with 10-year
survival of 83.5% and 78% (P = 0.595) and 10-year
disease-free survival 82.9% and 80.4% (P = 0.698) in
the lap-assisted and open group, respectively [51]. In the
COREAN trial that randomized 170 patients in each arm
to laparoscopic and open surgery for mid or low rectal can-
cer after preoperative chemoradiotherapy, the laparoscopic
grouphadloweramountofbloodloss,longeroperativetime,
quicker recovery of bowel function, and a lesser amount of
analgesic requirement. Surgical quality indicators including
the circumferential resection margin, macroscopic quality
of the TME specimen, number of harvested lymph nodes,
and perioperative morbidity were similar between groups
[52]. In a Spanish randomized trial of 204 patients of whom
78.6% in the open group and 76.2% in the laparoscopic
group underwent sphincter-preserving surgery; blood loss
was greater in the open surgery group, operative time
was longer in the laparoscopic group, and return to diet
and hospital stay was longer in the open surgery group.
Complication rates were similar between groups but a larger
number of lymph nodes were isolated in the laparoscopic
group [53]. Together, these three small randomized trials
suggest that the laparoscopic approach achieves improved
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quality of rectal cancer operations in skilled hands but a
longer operative time is required. Longer followup of these
trials and results of ongoing larger trials will conﬁrm the
long-term oncologic outcomes of laparoscopic rectal cancer
surgery.
1.2.2. Sequencing of Multimodality Therapy. Thorough pre-
operative clinical staging is paramount in the sequencing
of multimodality therapy for rectal cancer. For smaller
tumors T1/T2, surgery alone with wide surgical resection
of low anterior resection or abdominoperineal resection for
distal lesions not amendable to low anterior resection may
be performed. This allows sampling of mesorectal lymph
node for accurate pathological staging. In patients who
are medically unﬁt or who adamantly refuse to undergo
standardized resectional surgery, local excision with or
without chemoradiotherapy may be considered an option to
palliate early-stage disease. This strategy fails to sample the
mesorectal lymph nodes that are essential in disease staging.
In a large single institution cohort study comparing their
retrospective experience of 350 with stage I rectal cancer
of whom 283 patients (80.9%) underwent standardized
resection and 67 patients (19.1%) undergoing local excision,
5-year local recurrence was 14.1% in the local excision group
compared to 3.3% in the standardized resection group [54].
This signiﬁcantly higher local recurrence rate may then
be salvaged through multimodality approach combining
preoperative chemoradiotherapy and surgery. However, at
times, these local recurrences may not be resected with
standardized resectional surgery and may require radical
s u r g e r i e ss u c ha sap e l v i ce x e n t e r a t i o n .
For clinically staged T3/T4 rectal tumors without clin-
ically identiﬁed nodal disease (stage II) who undergo
TME surgery with either a low anterior resection or
abdominoperineal resection with harvesting of at least 12
lymph nodes examined and staged as pN0 chemoradia-
tion is not required. Chemoradiation may be considered
in the setting of pT3N0 tumors with adverse pathologic
features, non-TME surgery or in those with fewer than
12 lymph nodes harvested. For T3/T4 tumors with lymph
node metastases (stage III) identiﬁed clinically, treatment
involves both chemoradiation with ﬂuorouracil (5-FU) and
total mesorectal excision (TME) based surgery. However,
there remain enormous controversies regarding the optimal
sequence of these therapies. Postoperative chemoradiation
was shown to achieve superior results over postoperative
radiation alone with a 34% reduction in recurrence rate
with reductions observed for local recurrences and distant
metastasis [55]. When postoperative chemotherapy was
compared to radiotherapy in the NSABP R-01 randomized
trial, postoperative chemotherapy appeared to improve sur-
vival and radiotherapy reduced the incidence of locoregional
recurrence without survival improvements [56]. Given the
beneﬁts of chemoradiation in achieving local control as
an adjunct to surgery, the German Rectal Cancer Study
Group then conducted a randomized trial of 421 patients
to determine the perisurgical sequencing of chemoradiation
for rectal cancer. These investigators compared preoperative
to postoperative chemoradiation and demonstrated that the
5-year cumulative incidence of local recurrence was 6% in
the preoperative arm compared to 13% in the postoperative
arm (P = 0.006) with fewer grad 3/4 acute and long-term
toxic eﬀects of chemoradiation observed in the preoperative
arm compared to the postoperative arm [57]. In a smaller
Korean trial, the improved eﬀects of local control was
not demonstrated in the preoperative compared to the
postoperative chemoradiation arm, however, it was shown
that an increased rate of sphincter preservative surgery could
be achieved [58]. The exact type of preoperative therapy was
also recently debated with a short course radiation (25Gy
in 5 fractions) followed by surgery a week after or a long
course chemoradiation (50.4Gy in 28 fractions combined
with systemic chemotherapy) followed by surgery four to six
weeks after. The brief use of radiotherapy in the short course
setting has been argued upon its role in providing adequate
t u m o rr e s p o n s et oa l l o ws p h i n c t e rp r e s e r v a t i v es u r g e r y .T w o
randomized trials; Polish (n = 312) and Australian (n =
326) compared these two regimens and both trials showed a
lower rate of early acute toxicity and reduce cost of treatment
without any diﬀerence in long-term oncologic outcomes
[59, 60].
After preoperative chemoradiation, guidelines recom-
mendadjuvantchemotherapyforpatientswithnodepositive
disease. However, the EORTC 22921 trial of 785 clinically
staged T3/T4 rectal cancer patients randomized to receive
adjuvant ﬂuorouracil based chemotherapy after preoperative
(chemo) radiotherapy and surgery showed no survival
beneﬁt of chemotherapy on disease-free survival. However,
speciﬁc subgroup analysis was performed to determine the
appropriate role of adjuvant chemotherapy and showed that
pathologically staged T0-2 (ypT0-2) patients appeared to
beneﬁt in terms of both disease-free and overall survival
fromadjuvantchemotherapycomparedtoypT3/T4patients.
Importantly, adjuvant chemotherapy did not appear to
demonstrate any diﬀerence in outcomes of patients with
ypN0 or ypN+ disease. This demonstrates that further bene-
ﬁts of adjuvant chemotherapy are only observed in respond-
ing patients (ypT0-2) [61]. Further trials are required in
this area to determine the appropriate role of adjuvant
chemotherapy and the selection of high-risk populations
who may then beneﬁt from other modern adjuvant agents.
2. Role of Surgery for Advanced and
MetastaticRectalCancer
2.1. Locally Advanced or Local Recurrence. Tumors extending
beyond the rectal wall with invasion into surrounding
viscera are considered locally advanced rectal cancer. Often
in patients who develop local recurrence, recurrent dis-
ease often similarly involve adjacent structures where the
previously excised rectal tumor was located. Although its
incidence has decreased following total mesorectal excision
andtheincorporationofpreoperativechemoradiation,when
it occurs, it remains a debilitating condition that is diﬃcult
to treat. Palliative radiotherapy may provide brief symptom
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in these patients being between 12 and 24 months [62–
64]. Surgery may provide a long-term palliation to the
debilitating symptoms of pelvic recurrences. In the curative
setting,deliveryoflongcoursepreoperativechemoradiother-
apy may induce tumor down-staging to facilitate surgical
resection. In a randomized trial comparing neoadjuvant
radiotherapy to chemoradiotherapy in 207 patients with
locally unresectable T4 primary rectal or local recurrent
rectal cancer, chemoradiotherapy compared to radiotherapy
facilitated higher potential for an R0 resection (84% versus
68%; P = 0.009), improved local control in patients who
underwent a R0 or R1 resection (82% versus 67% at 5
years; P = 0.03), improved time to treatment failure (63%
versus 44%; P = 0.003), cancer-speciﬁc survival (72%
versus 55%; P = 0.02) and overall survival (66% versus
53%; P = 0.09) [65]. The surgery involved necessitated
pelvic exenteration where adjacent organs are resected with
an aim to achieve clear margins. In patients with primary
T4 rectal cancer and recurrent rectal cancer, 28% and
20% of patients in the chemoradiotherapy arm and 27%
and 46% in the radiotherapy arm, respectively, required
exenteration. Intraoperative radiotherapy (external-beam)
(IORT) is another approach to improve local control. This
treatment modality has been investigated in patients with
locally advanced unresectable rectal cancer after chemora-
diotherapy down-staging and surgery. Its application is best
used in the setting of a complete resection. Valentini et
al. reported 100 patients with T4M0 tumors undergoing
R0 resection after down-staging by chemoradiotherapy and
showed that 5-year local control was 90% in patients with
R0 surgery and 100% in patients with R0 surgery and IORT.
Further, IORT did not appear to compensate for suboptimal
surgery with 5-year overall survival of 68% observed in
patients with R0 surgery compared to 22% in R1 or R2
surgery [66]. Such radical surgery however is not widely
performed and only available in specialized institutions. In
a pattern of care study of the United States population
through data identiﬁed from the Surveillance, Epidemiology
and End Results (SEER) registry, only 33% of patients
with locally advanced adherent colorectal cancer underwent
multivisceral resection for which was shown to be associated
with improved overall survival [67].
2.2. Liver Metastases. In patients with synchronous rectal
cancer with liver metastases, there remains an enigma over
the appropriate sequencing of chemotherapy, radiotherapy,
and surgery. In a study from the Erasmus University, van
der Pool et al. reported a consecutive series of 57 patients of
whom29patientsunderwentresectionoftheprimarytumor
ﬁrst, 8 patients underwent simultaneous rectal and liver
resection and 20 underwent a liver-ﬁrst approach achieving
a median survival of 47 months and 5-year survival of
38%. This was achieved in a multidisciplinary setting where
an individualized approach towards treatment was taken.
In general, if resection of both primary tumor and liver
metastases may be completed in one surgery, this approach
may be favored. If the liver metastases are not completely
resectable during the rectal surgery or are too advanced
for hepatectomy irrespective, neoadjuvant chemotherapy is
preferred followed by a liver-ﬁrst approach followed by
restaging and preoperative radiotherapy and rectal surgery.
In patients with metachronous liver metastases, the evidence
of hepatectomy is based on current literature available for
colorectal liver metastases. Results of large clinical series have
shown that median survival range from 43 months to 64
months with 5-year survival ranging between 37% to 51%
[68, 69]. Of note, in a large international multi-institutional
registry study, rectal primary tumor were associated with
extrahepatic recurrences after hepatectomy for liver metas-
tases, hence emphasizing the importance of local control in
the pelvis [69]. However, there is no diﬀerence in colon or
rectal based primary tumor site impacting outcomes after
hepatectomy for colorectal liver metastases [70].
2.3. Lung Metastases. Epidemiological and observatory data
from the followup of patients with curatively treated col-
orectal cancer have shown that rectal cancer patients have a
higher preponderance to developing recurrence in the lungs
[71–73]. In a large population based study of 30 years in
Burgundy(France),Mitryetal.reportedthatlungmetastases
often accompanied liver metastases with synchronous lung
metastases being more common in left colonic and rectal
cancers [71–73]. Surgery for lung metastases is indicated
if the lung metastases are the only site of disease and a
complete resection may be achieved. Where extrapulmonary
metastases are present, a highly selective approach should
be taken often after adequate tumor response to systemic
chemotherapy to select patients whose disease is amendable
to resection of both lung and extra-pulmonary metastases.
The highest level of evidence for resection of lung metastases
comes from a large systematic review of 20 published
studies for pulmonary metastasectomy for colorectal lung
metastases. Pfannschmidt et al. report a median 5-year
overall survival of 40% in this selected group of patients
who underwent surgery [74]. Site of the primary tumor
did not result in diﬀerent survival outcome. However, given
that the liver will often be involved when there is lung
metastases, it is important that the selection of patients
for pulmonary metastasectomy should include a suﬃcient
disease-free interval from previous liver resection, use of
prethoracotomy CEA levels and the absence of mediastinal
lymph node involvement as a separate selection criteria
in this group of patients. Presently, a randomized trial
(PulMiCC) funded by Cancer Research UK is seeking to
investigate if pulmonary metastasectomy contributes to
improved survival of patients with colorectal lung metastases
by randomizing patients with a history of resected colorectal
cancer who are found to have pulmonary metastases to
be randomly allocated to “active monitoring” or “active
monitoring with pulmonary metastasectomy” with overall
survival, relapse-free survival, lung function, and patient-
reported quality of life as endpoints of this clinical trial
[75].
2.4. Peritoneal Metastases. Shedding of tumor during the
diﬃcult abdominoperineal resection, low anterior resection6 International Journal of Surgical Oncology
operation, or invasion of a large T3/T4 tumor in the
upper rectum above the peritoneal reﬂection may result
in the shedding of free peritoneal tumor cells within the
abdominopelvicperitonealcavity.Thegrowthandimplanta-
tionofthesecellsmayresultinthedevelopmentofperitoneal
metastases(carcinomatosis).Resultsofcytoreductivesurgery
and hyperthermic intraperitoneal chemotherapy (HIPEC)
have shown that this combined modality technique allows
complete excision of peritoneal tumors with locoregional
control achieved through the chemoperfusate. In colorectal
cancer, a randomized trial comparing cytoreductive surgery
and HIPEC demonstrated a median survival of 22.3 months
compared to 12.6 months in patients receive systemic
chemotherapy with or without palliative surgery [76]. The
two-fold survival beneﬁt provides evidence of its eﬃcacy.
However, in this trial of 105 patients, only 12 patients had
rectal cancer. Again, in a large registry study of the French
experience of HIPEC in colorectal cancer, of 523 patients
included, only 36 patients (7%) had primary colorectal
tumor of rectal origin [77]. In another international reg-
istry of 506 patients with colorectal peritoneal metastases
undergoing cytoreductive surgery and HIPEC, there were
40 patients (8%) with the primary tumor of rectal origin
and the median survival of these patients was 19.2 months
compared to 24 months in patients with tumors of sigmoid
origin, 17 months for patients with tumors of the right
colon and 20 months for patients with tumors of the
left colon [78]. These results inform us that peritoneal
metastases from rectal cancer is less common but prevent us
from drawing any meaningful conclusion on whether there
may be disparate survival outcomes for colon and rectal
cancer patients with peritoneal metastases. Based on the
currently available evidence, selected rectal cancer patients
withlimited peritonealdiseaseburdenmaybeconsideredfor
cytoreductive surgery and HIPEC.
3. Conclusion
Rectal cancer surgery has made signiﬁcant advancement
at all-time points of the natural history of this disease.
There are now minimally invasive local excision options that
are currently being tested for eﬃcacy as we await further
clinical trials to verify its eﬃcacy for pre-invasive and early
lesions. Laparoscopic rectal cancer surgery incorporating
total mesorectal excision is now emerging as the standard
surgical approach with ongoing clinical trials that will
conﬁrm its short and long-term oncologic eﬃcacy. There
is now evidence based results from clinical trials for both
preoperative short and long-course chemoradiation prior to
surgery for resectable tumors for which has been shown
to improve local control of disease albeit its aim achieving
sphincter preservative surgery where possible. Ultimately,
the goal of this being to achieve adequate sampling of
mesorectal lymph nodes to provide adequate information
for tumor staging and prediction of local and distant
recurrences for which will guide treatment decisions. There
is now evidence for resecting metastases from rectal cancer
from local recurrences, liver, lung, and peritoneal metastases
based on a body of retrospective clinical data with long-
term followup.
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